Chemical industry – Page 72
-
-
BusinessUS poised to approve its first ‘biosimilar’ drug
FDA panel recommends Sandoz’s copy of Amgen’s Neupogen
-
-
BusinessRevlon’s former chief scientist claims he was fired over safety whistleblowing
Ex-employee sues firm alleging job loss was the result of raising safety concerns that the company’s chief executive didn’t want to hear
-
-
Business
EU recommends Parkinson’s drug for approval
First new molecule for a decade, but Alzheimer’s still posing challenges as antibody treatment withdrawn from trials
-
Business
EU chemicals regulator scolded over animal testing
Ombudsman says ECHA isn’t doing enough to require alternative, non-animal methods
-
Business
Consumer products firms fined for French price fixing
€950m fines for ‘friends clubs’ that pushed up prices for home and personal care products
-
Business
Freedom Industries’ president arrested for fraud
Executive whose company leaked MCHM into West Virginian water supplies is charged with lying to deflect blame
-
BusinessMerck & Co to buy antibiotics specialist Cubist
Pharma giant remains committed to $9.5bn deal despite key Cubist patents being invalidated by court ruling
-
BusinessSolving iron’s solubility problem
Technology profile: MRC Human Nutrition Research - anaemia supplements with fewer side effects
-
Business
Saint-Gobain surprises Sika with buyout bid
Company is buying out family-owned controlling stake, but Sika claims the deal will create a conflict of interest
-
Business
Big pharma opens up abandoned drugs
Seven firms will make 68 stalled compounds available for academic research
-
Business
Huntsman looks to cut jobs and titania capacity
900 employees face axe as firm evaluates titanium dioxide options
-
BusinessGSK cuts US jobs in push for savings
Research Triangle Park site bears the brunt as drugmaker consolidates research in Philadelphia and Stevenage, UK
-
Business
Otsuka to buy neurology specialist Avanir
$3.5bn deal adds to Otsuka’s mental health portfolio and strengthens its US presence
-
BusinessCystic Fibrosis Foundation sells drug royalty rights for $3.3bn
‘Venture philanthropy’ model pays off with massive cash injection for charity
-
Business
DuPont quantifies scale of deadly chemical leak
10.4 tonnes of methyl mercaptan were released in La Porte, US
-
OpinionProgress at the pace of the slowest
Chemistry is rarely the rate-limiting process in getting a drug to market, says Derek Lowe
-
Business
UCB sells speciality generics subsidiary
Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology